Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials

Cindy J Nowinski*, Deborah M. Miller, David Cella

*Corresponding author for this work

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Patient-reported outcomes (PROs) are playing an increasing role in multiple sclerosis (MS) research and practice, and are essential for understanding the effects that MS and MS treatments have on patients’ lives. PROs are captured directly from patients and include symptoms, function, health status, and health-related quality of life. In this article, we review different categories (e.g., generic, targeted, preference-based) of PRO measures and considerations in selecting a measure. The PROs included in MS clinical research have evolved over time, as have the measures used to assess them. We describe findings from recent MS clinical trials that included PROs when evaluating Food and Drug Administration-approved disease-modifying therapies (e.g., daclizumab, teriflunomide). Variation in the measures used in these trials makes it difficult to draw any conclusions from the data. We therefore suggest a standardized approach to PRO assessment in MS research and describe 2 generic, National Institutes of Health-supported measurement systems [Neuro-QoL and the Patient-Reported Outcomes Measurement Information System (PROMIS)] that would facilitate such an approach. The use of PROs in MS care and research is expanding beyond clinical trials, as is demonstrated by examples from comparative effectiveness and other patient-centered research. The importance of PRO assessment is expected to continue to grow in the future.

Original languageEnglish (US)
Pages (from-to)934-944
Number of pages11
JournalNeurotherapeutics
Volume14
Issue number4
DOIs
StatePublished - Oct 1 2017

Fingerprint

Multiple Sclerosis
Clinical Trials
Patient Outcome Assessment
Research
Patient Reported Outcome Measures
National Institutes of Health (U.S.)
United States Food and Drug Administration
Information Systems
Health Status
Quality of Life
Therapeutics

Keywords

  • Clinical trials
  • Health-related quality of life
  • Multiple sclerosis
  • Patient-reported outcomes

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

@article{6a1dc63aa1e44a9bb4cd28b8430d77c2,
title = "Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials",
abstract = "Patient-reported outcomes (PROs) are playing an increasing role in multiple sclerosis (MS) research and practice, and are essential for understanding the effects that MS and MS treatments have on patients’ lives. PROs are captured directly from patients and include symptoms, function, health status, and health-related quality of life. In this article, we review different categories (e.g., generic, targeted, preference-based) of PRO measures and considerations in selecting a measure. The PROs included in MS clinical research have evolved over time, as have the measures used to assess them. We describe findings from recent MS clinical trials that included PROs when evaluating Food and Drug Administration-approved disease-modifying therapies (e.g., daclizumab, teriflunomide). Variation in the measures used in these trials makes it difficult to draw any conclusions from the data. We therefore suggest a standardized approach to PRO assessment in MS research and describe 2 generic, National Institutes of Health-supported measurement systems [Neuro-QoL and the Patient-Reported Outcomes Measurement Information System (PROMIS)] that would facilitate such an approach. The use of PROs in MS care and research is expanding beyond clinical trials, as is demonstrated by examples from comparative effectiveness and other patient-centered research. The importance of PRO assessment is expected to continue to grow in the future.",
keywords = "Clinical trials, Health-related quality of life, Multiple sclerosis, Patient-reported outcomes",
author = "Nowinski, {Cindy J} and Miller, {Deborah M.} and David Cella",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s13311-017-0571-6",
language = "English (US)",
volume = "14",
pages = "934--944",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "4",

}

Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials. / Nowinski, Cindy J; Miller, Deborah M.; Cella, David.

In: Neurotherapeutics, Vol. 14, No. 4, 01.10.2017, p. 934-944.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials

AU - Nowinski, Cindy J

AU - Miller, Deborah M.

AU - Cella, David

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Patient-reported outcomes (PROs) are playing an increasing role in multiple sclerosis (MS) research and practice, and are essential for understanding the effects that MS and MS treatments have on patients’ lives. PROs are captured directly from patients and include symptoms, function, health status, and health-related quality of life. In this article, we review different categories (e.g., generic, targeted, preference-based) of PRO measures and considerations in selecting a measure. The PROs included in MS clinical research have evolved over time, as have the measures used to assess them. We describe findings from recent MS clinical trials that included PROs when evaluating Food and Drug Administration-approved disease-modifying therapies (e.g., daclizumab, teriflunomide). Variation in the measures used in these trials makes it difficult to draw any conclusions from the data. We therefore suggest a standardized approach to PRO assessment in MS research and describe 2 generic, National Institutes of Health-supported measurement systems [Neuro-QoL and the Patient-Reported Outcomes Measurement Information System (PROMIS)] that would facilitate such an approach. The use of PROs in MS care and research is expanding beyond clinical trials, as is demonstrated by examples from comparative effectiveness and other patient-centered research. The importance of PRO assessment is expected to continue to grow in the future.

AB - Patient-reported outcomes (PROs) are playing an increasing role in multiple sclerosis (MS) research and practice, and are essential for understanding the effects that MS and MS treatments have on patients’ lives. PROs are captured directly from patients and include symptoms, function, health status, and health-related quality of life. In this article, we review different categories (e.g., generic, targeted, preference-based) of PRO measures and considerations in selecting a measure. The PROs included in MS clinical research have evolved over time, as have the measures used to assess them. We describe findings from recent MS clinical trials that included PROs when evaluating Food and Drug Administration-approved disease-modifying therapies (e.g., daclizumab, teriflunomide). Variation in the measures used in these trials makes it difficult to draw any conclusions from the data. We therefore suggest a standardized approach to PRO assessment in MS research and describe 2 generic, National Institutes of Health-supported measurement systems [Neuro-QoL and the Patient-Reported Outcomes Measurement Information System (PROMIS)] that would facilitate such an approach. The use of PROs in MS care and research is expanding beyond clinical trials, as is demonstrated by examples from comparative effectiveness and other patient-centered research. The importance of PRO assessment is expected to continue to grow in the future.

KW - Clinical trials

KW - Health-related quality of life

KW - Multiple sclerosis

KW - Patient-reported outcomes

UR - http://www.scopus.com/inward/record.url?scp=85029517030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029517030&partnerID=8YFLogxK

U2 - 10.1007/s13311-017-0571-6

DO - 10.1007/s13311-017-0571-6

M3 - Review article

VL - 14

SP - 934

EP - 944

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 4

ER -